New myelofibrosis data sharpen Lilly’s AJ1-11095 JAK2 inhibitor profile

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 2:45 PM ET. Details in the imprint.

Eli Lilly and Company is putting fresh clinical momentum behind its investigational myelofibrosis therapy AJ1-11095, an oral type II JAK2 inhibitor that has just produced encouraging Phase 1 results in patients who previously received a type I JAK2 drug. According to Lilly’s latest update on the AJX-101 study, the candidate showed a manageable safety profile alongside meaningful reductions in spleen size and symptom burden, positioning AJ1-11095 as one of the company’s most closely watched hematology assets. Lilly summarized the initial AJX-101 findings ahead of the 2026 EHA Annual Meeting.

What Lilly’s AJ1-11095 is designed to do in myelofibrosis

AJ1-11095 is described by Lilly as a first-in-class, oral type II JAK2 inhibitor developed for patients with myelofibrosis whose disease has already been treated with a type I JAK2 inhibitor, such as ruxolitinib, but remains uncontrolled or has progressed. In the ongoing global, open-label Phase 1 AJX-101 trial, the drug is being evaluated in people with primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis, all of whom had previously received a type I JAK2 agent. Lilly reports that AJ1-11095 achieved a spleen volume reduction of at least 35 percent (SVR35) as best response in 70 percent of enrolled patients, a key efficacy marker in this disease setting, and a 50 percent or greater improvement in total symptom score (TSS50) was also seen in 70 percent of patients at week 12. In addition, reductions in driver mutation variant allele frequency were documented in 21 out of 23 patients, including those with JAK2, MPL and CALR type 1 and type 2 mutations, a biologic effect that is described as uncommon with existing type I JAK2 inhibitors. The AJX-101 listing on ClinicalTrials.gov outlines the dose-escalation design and inclusion criteria for AJ1-11095.

On the safety side, Lilly states that no dose-limiting toxicities have been observed so far in the AJX-101 dose-escalation phase, and that 78 percent of participants in this portion of the study remain on treatment. The most common treatment-emergent adverse events include anemia, dysgeusia, decreases in platelet count and increases in alanine aminotransferase, events that treating physicians will need to weigh against the potential clinical benefits as development progresses. The company has moved AJ1-11095 into an expansion cohort focused on second-line myelofibrosis and is planning further studies in high-risk polycythemia vera and in myelofibrosis patients who are JAK2 inhibitor-naïve, signaling that Lilly sees broader myeloproliferative potential for the molecule if future data remain supportive. For hematologists and specialized centers, AJ1-11095 may, over time, represent an additional option in a therapeutic area where many patients ultimately exhaust currently available JAK inhibition strategies.

The strategic relevance of AJ1-11095 inside Lilly’s broader portfolio is tied less to near-term revenue and more to diversification beyond its dominant diabetes and obesity franchises, where products like tirzepatide have transformed the company’s growth profile. Management has repeatedly highlighted oncology and hematology as priority investment areas, and an effective type II JAK2 inhibitor with a differentiated clinical and molecular profile could help cement the company’s role in myeloproliferative diseases dominated today by other manufacturers. According to market data, Eli Lilly and Company’s shares (ISIN US5324571083) traded on the NYSE at around $119.40 on 06/13/2026, reflecting investors’ focus on its late-stage pipeline and commercial launches. NYSE quote data show LLY near record territory in mid-2026.

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.